Condition
SSTR2
Total Trials
2
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
Early P 1 (1)
Trial Status
Recruiting2
Clinical Trials (2)
Showing 2 of 2 trials
NCT07301801Early Phase 1Recruiting
Clinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors
NCT05873777Not ApplicableRecruitingPrimary
68Ga-FAPI-LM3 PET/CT Imaging in Patients With FAP/SSTR2 Positive Disease and Compared With 18F-FDG
Showing all 2 trials